Form 4: Capricor Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Karen Krasney, EVP and General Counsel at Capricor Therapeutics, exercised stock options and acquired 8,000 shares of common stock.
Summary
- Karen Krasney, an executive at Capricor Therapeutics, exercised stock options on December 13, 2024.
- She acquired 8,000 shares of common stock at a price of $1.39 per share.
- This transaction increased her direct holdings to 28,047 shares.
- The exercised options were from grants made in 2015 and 2016, which were adjusted due to a reverse stock split and share reprice.
- The 2015 option was originally for 30,000 shares at $5.78, and the 2016 option was for 50,000 shares at $3.12, both adjusted to $1.39 after a 1-for-10 reverse split and a share reprice.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to stock option exercises, which is neither positive nor negative in itself. It reflects standard executive compensation practices.
Positives
- The executive's exercise of options could be seen as a positive sign of confidence in the company's future.
Risks
- Executive stock transactions can sometimes be interpreted as a signal of insider sentiment, which could impact market perception.
Industry Context
This is a routine filing related to executive compensation and is common in publicly traded companies. It does not indicate any specific industry trend.
Comparison to Industry Standards
- Stock option exercises are a standard form of executive compensation in the biotechnology industry.
- The adjustments to the options due to the reverse split and share reprice are not uncommon for companies experiencing stock price volatility.
- Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/03/2015 | Date of original grant of stock option covering 30,000 shares at $5.78 per share, later adjusted. |
| 06/02/2016 | Date of original grant of stock option covering 50,000 shares at $3.12 per share, later adjusted. |
| 06/04/2019 | Date of 1-for-10 reverse stock split. |
| 02/12/2020 | Date of share reprice to $1.39 per share. |
| 12/13/2024 | Date of stock option exercise and acquisition of 8,000 shares. |
| 12/16/2024 | Date of filing of the SEC Form 4. |
Keywords
stock options, insider trading, executive compensation, Capricor Therapeutics, CAPR, Karen Krasney, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.